Last reviewed · How we verify
USWM, LLC (dba US WorldMeds) — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| lofexidine HCl | lofexidine HCl | marketed | Alpha-2 adrenergic agonist | Alpha-2 adrenergic receptor | Addiction Medicine / Substance Use Disorder | |
| Open Label Lofexidine HCL | Open Label Lofexidine HCL | phase 3 | Alpha-2 adrenergic agonist | Alpha-2 adrenergic receptor | Addiction Medicine / Substance Use Disorder |
Therapeutic area mix
- Addiction Medicine / Substance Use Disorder · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American University of Beirut Medical Center · 1 shared drug class
- China International Neuroscience Institution · 1 shared drug class
- Derm Research, PLLC · 1 shared drug class
- Eye Therapies, LLC · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Guangzhou Women and Children's Medical Center · 1 shared drug class
- Icahn School of Medicine at Mount Sinai · 1 shared drug class
- Al-Azhar University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for USWM, LLC (dba US WorldMeds):
- USWM, LLC (dba US WorldMeds) pipeline updates — RSS
- USWM, LLC (dba US WorldMeds) pipeline updates — Atom
- USWM, LLC (dba US WorldMeds) pipeline updates — JSON
Cite this brief
Drug Landscape (2026). USWM, LLC (dba US WorldMeds) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/uswm-llc-dba-us-worldmeds. Accessed 2026-05-17.